Biological Products, (No Diagnostic Substances) · DE · CIK 1649094
Vaxcyte engineers high-fidelity vaccines using cell-free synthesis to combat bacterial diseases
Comparable business profile · signals at a glance
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
In the 90 days to Mar 17, 2026: 3 sold $1.7M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 17, 2026 | Cowan ElviaSVP, Finance & CAO | Sell | 1,487 | $55.39 | $82K |
| Mar 17, 2026 | Cowan ElviaSVP, Finance & CAO | Sell | 405 | $56.26 | $23K |
| Mar 11, 2026 | Cowan ElviaSVP, Finance & CAO | Sell | 2,500 | $58.59 | $146K |
| Mar 10, 2026 | Wassil JimCHIEF OPERATING OFFICER | Sell | 4,968 | $59.16 | $294K |
| Mar 10, 2026 | Wassil JimCHIEF OPERATING OFFICER | Sell | 2,427 | $58.32 | $142K |
| Dec 31, 2025 | Dhaliwal Harpreet S.Chief Technical Ops Officer | Sell | 9,743 | $46.69 | $455K |
| Dec 23, 2025 | Cowan ElviaSVP, FINANCE | Sell | 6,716 | $47.94 | $322K |
| Dec 23, 2025 | Cowan ElviaSVP, FINANCE | Sell | 4,907 | $47.90 | $235K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.